AI Article Synopsis
- The DreaMM-7 and -8 trials showcase the effectiveness of triplet combination treatments that include the drug belantamab mafodotin for relapsed myeloma patients.
- The trials provide important data on both how well the treatments work (efficacy) and their safety for patients.
- The findings could influence future strategies for using belantamab in treating relapsed myeloma, highlighting its potential benefits in clinical practice.
Article Abstract
The recently published DreaMM-7 and -8 trials demonstrate the benefit of triplet combination regimens including the anti-BCMA antibody drug conjugate belantamab mafodotin. Here, we describe the findings of these trials including efficacy and safety data and provide commentary on the implications for future use of belantamab in the relapsed myeloma space.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.medj.2024.07.027 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
How to rescue a DreaMM deferred ….
Med
September 2024
Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.
The recently published DreaMM-7 and -8 trials demonstrate the benefit of triplet combination regimens including the anti-BCMA antibody drug conjugate belantamab mafodotin. Here, we describe the findings of these trials including efficacy and safety data and provide commentary on the implications for future use of belantamab in the relapsed myeloma space.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!